Appili Receives US$1.2M Grant

Appili Theraputics, an anti-infective drug development company, received a US$1.2 million (C$1.5 million) grant from the U.S. Department of Defense’s Peer Reviewed Medical Research Program.
The Halifax company said in a press release it will use the funds to develop a compound for its ATI-1503 antibiotic program. ATI-1503 will be able to treat drug-resistant bacteria called Gram-negative